VIDEO: Venetoclax yields quality of life benefits in AML patients
Venetoclax plus azacitidine or low-dose cytarabine had a positive impact on the health-related quality of life of patients with acute myeloid leukemia who were ineligible for intensive chemotherapy, according to a presentation at the ASH Annual Meeting and Exposition.
In an analysis from two phase 3 trials, Keith W. Pratz, MD, director of the Leukemia Program at Penn Medicine, and colleagues examined health-related quality of life in patients with AML receiving venetoclax co-administered with azacitidine (the Viale-A study) or low-dose cytarabine (the Viale-C study). They observed significant improvements in measures of quality of life in both studies.
“The take home message from the study group here is that consistent with the clinical outcomes of improved CR rates and improved disease-free overall survival, we also show maintenance of quality of life throughout the treatment courses in patients given venetoclax over those given placebo, regardless of whether they went into remission or not,” Pratz said. “This is an important finding in that it’s not just remission status, it’s the maintenance quality of life in these patients given venetoclax and it justifies it’s use as a standard approach in these patients.”
Collapse
Pratz KW, et al. Abstract 589. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about